Nephro Care

Why is Nephro Care India Ltd falling/rising?

As of 11-Aug, Nephro Care India Ltd's stock price is rising to 83.50, up 4.97%. This increase is driven by strong sector performance, heightened investor participation, and favorable short-term moving averages, despite being below the 200-day moving average.

As of 11-Aug, Nephro Care India Ltd's stock price is rising, currently at 83.50, reflecting a change of 3.95 or 4.97% increase. This upward movement can be attributed to several factors. Firstly, the stock has significantly outperformed the sector today by 6.03%. Additionally, there has been a notable increase in investor participation, with a delivery volume of 1.06 lacs on 10 August, which is up by 537.68% compared to the 5-day average delivery volume. <BR><BR>Moreover, the stock's current price is higher than its 5-day, 20-day, 50-day, and 100-day moving averages, indicating a positive short-term trend, although it remains below the 200-day moving average. This suggests that while the stock is experiencing a rise in the short term, it may still be in a longer-term downtrend. Overall, the combination of strong sector performance, increased trading activity, and favorable moving averages contributes to the current rise in Nephro Care India Ltd's stock price.

Which are the latest news on Nephro Care?

What does Nephro Care do?

Nephro Care India Ltd, a micro-cap company established in 2014, operates in the hospital industry, reporting net sales of 27 Cr and a net profit of 1 Cr for the quarter ending March 2026. Key metrics include a P/E ratio of 35.00 and a market cap of INR 123 Cr.

Overview:<BR>Nephro Care India Ltd operates in the hospital industry and is classified as a micro-cap company.<BR><BR>History:<BR>Nephro Care India Limited was incorporated in 2014 as a Private Limited Company and later converted to a Public Limited Company. The latest quarterly results reported net sales and profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 27 Cr (Quarterly Results - Mar 2026)<BR>Net Profit: 1 Cr (Quarterly Results - Mar 2026)<BR>Market Cap: INR 123 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 35.00<BR>Industry P/E: 60<BR>Dividend Yield: 0.00%<BR>Debt-Equity: -0.29<BR>Return on Equity: 5.93%<BR>Price to Book: 2.15<BR><BR>Contact Details:<BR>Registrar Address: Not available.

How big is Nephro Care?

As of 10th June, Nephro Care India Ltd has a market capitalization of 123.00 Cr and reported net sales of 26.97 Cr with a net profit of 1.00 Cr for the latest quarter ending March 2026.

As of 10th June, <BR><BR>Market Cap: Nephro Care India Ltd has a market capitalization of 123.00 Cr, categorized as a Micro Cap.<BR><BR>Recent Quarterly Performance: For the latest quarter ending March 2026, the company reported Net Sales of 26.97 Cr and a Net Profit of 1.00 Cr.<BR><BR>Balance Sheet Snapshot: The latest annual reporting period is March 2025, with Shareholder's Funds amounting to 53.48 Cr and Total Assets of 68.28 Cr.

Who are the peers of the Nephro Care?

Nephro Care's peers include Vaidya Sane, KHFM Hospitality, Maitreya Medica, Sangani Hospital, Aatmaj Health, Abate As Indust, Fortis Malar, Aashka Hospitals, and Shanmuga Hospital. Nephro Care shows excellent management and growth, but has a 1-year return of -44.59%, lower than Vaidya Sane's 8.17%.

Peers: The peers of Nephro Care are Vaidya Sane, KHFM Hospitality, Maitreya Medica., Sangani Hospital, Aatmaj Health, Abate As Indust, Fortis Malar, Aashka Hospitals, Shanmuga Hos.<BR><BR>Quality Snapshot: Excellent management risk is observed at Nephro Care and Shanmuga Hos., while Average management risk is found at Vaidya Sane and Aatmaj Health, and the rest have Below Average management risk. Growth is Excellent at Nephro Care and Sangani Hospital, Average at Vaidya Sane and Aatmaj Health, while the rest have Below Average growth. Good capital structure is noted at Nephro Care, Sangani Hospital, and Aatmaj Health, while Average capital structure is found at Abate As Indust and Aashka Hospitals, and the rest have Below Average capital structure.<BR><BR>Return Snapshot: Nephro Care has a 1-year return of -44.59%, which is lower than Vaidya Sane's highest return of 8.17% and higher than KHFM Hospitality's lowest return of -28.83%. Additionally, peers with negative six-month returns include Nephro Care, KHFM Hospitality, Maitreya Medica., Sangani Hospital, and Abate As Indust.

How has been the historical performance of Nephro Care?

Nephro Care has experienced significant growth from March 2022 to March 2025, with net sales increasing from 3.42 Cr to 46.03 Cr, and total assets rising to 68.28 Cr. Despite fluctuations in profit metrics, the company shows a strong upward trend in financial performance and operational scaling.

Answer:<BR>The historical performance of Nephro Care shows significant growth over the years, particularly from March 2022 to March 2025.<BR><BR>Breakdown:<BR>Nephro Care's net sales have increased dramatically from 3.42 Cr in March 2022 to 46.03 Cr in March 2025, reflecting a strong upward trend. Total operating income followed a similar trajectory, rising from 3.42 Cr in March 2022 to 46.03 Cr in March 2025. The company's total expenditure also grew, reaching 40.16 Cr in March 2025 from just 3.30 Cr in March 2022. Operating profit, excluding other income, peaked at 5.87 Cr in March 2025, although it was slightly lower than the previous year's 6.47 Cr. Profit before tax showed fluctuations, with a high of 6.22 Cr in March 2024 but dropping to 4.83 Cr in March 2025. Profit after tax reached 3.64 Cr in March 2025, down from 4.50 Cr in March 2024, yet still a significant improvement from the loss of 0.01 Cr in March 2022. The company's total assets surged to 68.28 Cr in March 2025 from 4.63 Cr in March 2022, while total liabilities also increased to 68.28 Cr in March 2025, indicating a balanced growth in both assets and liabilities. Cash flow from operating activities improved to 7.00 Cr in March 2025, and the closing cash and cash equivalents rose to 4.00 Cr, showcasing a positive cash position. Overall, Nephro Care's financial metrics indicate robust growth and operational scaling over the past few years.

Is Nephro Care overvalued or undervalued?

As of September 11, 2025, Nephro Care is considered expensive with a PE ratio of 74.28 and remains overvalued compared to peers, having underperformed the Sensex with a return of -35.06% over the past year.

As of 11 September 2025, Nephro Care's valuation grade has moved from very expensive to expensive, indicating a slight improvement in its perceived value. However, the company remains overvalued based on its current financial metrics. The PE ratio stands at 74.28, the Price to Book Value is 5.06, and the EV to EBITDA ratio is 42.54, all of which are significantly higher than the industry averages.<BR><BR>In comparison to its peers, Nephro Care's valuation appears less favorable. For instance, Max Healthcare is categorized as very expensive with a PE ratio of 95.01, while Apollo Hospitals, considered fairly valued, has a PE ratio of 72.1. Despite this, Nephro Care's high valuation ratios suggest that it is overvalued relative to its peers. The company's stock has underperformed against the Sensex, particularly over the past year, with a return of -35.06% compared to the Sensex's modest gain of 0.35%.

Who are the top shareholders of the Nephro Care?

The top shareholder of Nephro Care is Pratim Sengupta, holding 60.71%, with individual investors owning 27.07% and 13 foreign institutional investors holding 3.5%. The highest public shareholder is Rohan Vinay Pai at 2.24%.

The top shareholders of Nephro Care include Pratim Sengupta, who is the promoter with the highest holding at 60.71%. The company has no pledged promoter holdings, and individual investors collectively hold 27.07% of the shares. Additionally, there are 13 foreign institutional investors (FIIs) that hold 3.5% of the company. The highest public shareholder is Rohan Vinay Pai, with a holding of 2.24%.

What is the technical trend for Nephro Care?

As of May 22, 2025, Nephro Care's trend is mildly bearish, indicated by bearish daily moving averages and Bollinger Bands, despite a mildly bullish weekly MACD, with the stock underperforming the Sensex by -27.72% year-to-date.

As of 22 May 2025, the technical trend for Nephro Care has changed from sideways to mildly bearish. The daily moving averages indicate a bearish stance, while the weekly MACD is mildly bullish, suggesting mixed signals. The weekly Bollinger Bands and KST are both bearish, reinforcing the negative outlook. Additionally, the stock has underperformed the Sensex significantly year-to-date, with a return of -27.72% compared to the Sensex's 6.17%. Overall, the current stance is mildly bearish, driven primarily by the bearish moving averages and Bollinger Bands.

When is the next results date for Nephro Care?

No Upcoming Board Meetings

Has Nephro Care declared dividend?

No Dividend History Available